Study 3 of 108 for search of: Spasticity
Previous Study Return to Search Results Next Study

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Vanderbilt University Spasticity Management Program Evaluation Plan
This study has been completed.
Sponsors and Collaborators: Vanderbilt University
Allergan
Medtronic
Information provided by: Vanderbilt University
ClinicalTrials.gov Identifier: NCT00179114
  Purpose

People with severe developmental disabilities frequently have comorbidities that make providing care to them more difficult. Spasticity is one such comorbidity. It produces increased muscle tone that can cause stiffness in joints and bodily contortions that can interfere with all of the major types of care provided to participants. Typically, care areas include splinting, hygiene, dressing, transfers, positioning, ambulation, and engaging in other functional activities. Moreover, persons with spasticity often experience pain.

Typically, spasticity is managed by health care providers using a combination of the following therapies:

  • Physical / occupational therapy (PT / OT)
  • Oral medication
  • Botox injections
  • Intrathecal baclofen administered by the Medtronic SyncroMed pump (ITB)
  • Orthopedic / neurological surgery

Condition Intervention Phase
Spasticity
Drug: Botulinum Toxin Type A
Drug: Intrathecal baclofen administered by the Medtronic SyncroMed(TM) pump (ITB)
Phase IV

MedlinePlus related topics: Botox Developmental Disabilities
Drug Information available for: Baclofen Clostridium botulinum toxin
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study
Official Title: Vanderbilt University Spasticity Management Program Evaluation Plan

Further study details as provided by Vanderbilt University:

Primary Outcome Measures:
  • Total time (in seconds) spent by caregivers to complete a defined care area task at one year followup.
  • Categorical rating by blinded, independent reviewer of baseline and one-year care area task videos.

Secondary Outcome Measures:
  • Range of motion score for each care area goal, assigned by physical therapist and compared at baseline vs. one-year followup.
  • Differences in the number of hospital admissions 12 months pre- and 12 months post-program.
  • Differences in costs associated with caregiving 12 months pre- and 12 months post-treatment.
  • Difference in Physician's global assessment of spasticity at baseline and one-year followup.

Estimated Enrollment: 20
Study Start Date: August 2002
Estimated Study Completion Date: February 2006
Detailed Description:

As individuals are identified as appropriate participants for the Program and consent is obtained, the care team for each person, consisting of both medical and caregiver staff, will define up to three specific care area goals and related tasks for treatment. A comprehensive spasticity management program will then be developed for the individual. Clinical and outcome assessments at baseline and at follow-up will include measures of range of motion, global spasticity according to a modified Ashworth scale, and the time and number of staff required for the task. In addition, video will be obtained of caregivers performing each participant's care area tasks at baseline and follow-up to allow an independent external reviewer to judge task difficulty. Treatment will be provided as outlined by the spasticity management plan. Follow-up evaluations will be conducted when the participant is at least one year from their initial Botulinum injection, or are one year post-implant for ITB participants. When the participant is exited from the study, Survey Physician will be asked to rate the overall impact of the Program on each of the individual's care area tasks.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adult with spasticity residing at Clover Bottom Developmental Center in Nashville, Tennessee.
  • Spasticity must interfere with daily functioning.
  • Care team must be able to identify at least one treatment goal for the potential participant.

Exclusion Criteria:

  • Family or guardian is unwilling to provide written informed consent.
  • Spasticity does not interfere with patient's day-to-day care.
  • Staff who provide daily care are unable to identify a clear treatment goal.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00179114

Locations
United States, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37212
Sponsors and Collaborators
Vanderbilt University
Allergan
Medtronic
Investigators
Principal Investigator: David Charles, MD Vanderbilt University Department of Neurology
  More Information

Study ID Numbers: SMPEP-9.1
Study First Received: September 13, 2005
Last Updated: August 17, 2007
ClinicalTrials.gov Identifier: NCT00179114  
Health Authority: United States: Food and Drug Administration

Keywords provided by Vanderbilt University:
Spasticity
Developmental Disabilities
Intrathecal baclofen (ITB)
Botulinum Toxin Type A (Botox)

Study placed in the following topic categories:
Developmental Disabilities
Signs and Symptoms
Muscle Spasticity
Botulinum Toxins
Muscular Diseases
Musculoskeletal Diseases
Muscle Hypertonia
Baclofen
Neurologic Manifestations
Botulinum Toxin Type A

Additional relevant MeSH terms:
Neuromuscular Manifestations
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Anti-Dyskinesia Agents
Nervous System Diseases
Physiological Effects of Drugs
Neuromuscular Agents
Pharmacologic Actions
Muscle Relaxants, Central
Therapeutic Uses
GABA Agonists
GABA Agents
Peripheral Nervous System Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on January 30, 2009